Sacubitril/valsartan Vs Ace Inhibitor Use In Patients With Heart Failure With Reduced Ejection Fraction And New York Heart Association - 4 Symptoms; A Propensity Score Matched Analysis

Sacubitril/Valsartan is the first-line medication for patients with heart failure with reduced ejection fraction (HFrEF), evidence for which has come largely from the Paradigm-HF trial. Patients with New York Heart Association - 4 symptoms (NYHA-4) were underrepresented in this landmark trial with them being
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Tags: 081 Source Type: research